Monoclonal antibodies
PreclinicalSmall molecule
Monoclonal antibodies is one of 13 small molecule programs targeting Macroglobulinemia. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Macroglobulinemia
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Imbruvica
PPharmacyclics LLC.
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Venclexta
AbbViePhase 2
Jaypirca
Eli LillyPhase 2
Brukinsa
BBeOne Medicines
Phase 2
Treanda
AAzurity Pharmaceuticals
Phase 2
Valtrex
GGlaxo Dba Glaxosmithkline
Phase 2
Vonjo
SSobi, Inc.
Phase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer1 trial
COVID-191 trial
Macroglobulinemia1 trial
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
Completed·—·N/A·NCT00142155·300 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Monoclonal antibodies. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTanta University